Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

15. Januar 2026 03:26 ET | Quelle: Digbi Health

Digbi Health Publishes Peer-Reviewed Data Demonstrating Significant Cost Savings for Employers Via Its Precision Biology Telehealth Platform to Manage GLP-1, Metabolic, and GI Costs

MOUNTAIN VIEW, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Digbi Health, the national leader in Precision Biology–based chronic care, today announced peer-reviewed, actuarially validated significant...
12. Januar 2026 08:30 ET | Quelle: Kailera Therapeutics, Inc.

Kailera Therapeutics Announces First Participants Randomized in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide (KAI-9531)

Kailera announced the first participants randomized in the global Phase 3 clinical program of GLP-1/GIP receptor dual agonist ribupatide (KAI-9531).
08. Januar 2026 07:30 ET | Quelle: Alveus Therapeutics Inc

Alveus Therapeutics Launches with $160 Million Series A Financing to Advance Next-Generation Therapies for Obesity and Metabolic Diseases

Financing supports Phase 2 development of ALV-100, IND filing of ALV-200 and advancement of additional programs across the R&D pipeline ALV-100, a bifunctional GIPR antagonist / GLP-1R agonist,...
08. Januar 2026 07:00 ET | Quelle: Rani Therapeutics, LLC

Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen

Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen
08. Januar 2026 07:00 ET | Quelle: Antag Therapeutics

Antag Therapeutics demonstrates compelling potential of its novel GIPR antagonist for obesity, reporting excellent tolerability in Phase 1 and enhanced weight loss in amylin combination study

Combination of AT7687 and cagrilintide demonstrated enhanced weight loss effect in obese, insulin-resistant, pre-diabetic non-human primate (NHP) modelAdditional weight loss observed in combination...
07. Januar 2026 13:01 ET | Quelle: King Faisal Prize

Pioneering Scientist Behind Revolutionary Weight-Loss Drugs and Leading Mathematician Honored with 2026 King Faisal Prize

Riyadh, Saudi Arabia, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Professor Svetlana Mojsov was announced this year's King Faisal Prize in Medicine laureate for her groundbreaking discoveries that are...
07. Januar 2026 08:00 ET | Quelle: Imbria Pharmaceuticals Inc.

Imbria Pharmaceuticals Announces Publication of IMPROVE-DiCE Phase 2a Data in Circulation, Demonstrating Ninerafaxstat as a Potential First-in-Class Therapy Targeting Cardiac Energetics in Cardiometabolic Disease

Data provide first human validation of cardiac energetics modulation as a therapeutic target in cardiometabolic heart disease, including heart failure with preserved ejection fraction (HFpEF) In...
06. Januar 2026 01:56 ET | Quelle: MindRank AI Ltd.

MindRank Initiates Phase III "MOBILE" Trial for MDR-001: an Oral GLP-1RA Small Molecule Engineered with AI

MindRank Initiates Phase III "MOBILE" Trial for MDR-001: an Oral GLP-1RA Small Molecule Engineered with AI
05. Januar 2026 08:05 ET | Quelle: Kailera Therapeutics, Inc.

Kailera Therapeutics Appoints Doug Pagán as Chief Financial Officer

Kailera Therapeutics today announced the appointment of Doug Pagán as its Chief Financial Officer.
23. Dezember 2025 09:00 ET | Quelle: Kailera Therapeutics, Inc.

Kailera Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

Kailera Therapeutics will present at the 44th Annual J.P. Morgan Healthcare Conference in January.

Nächste Seite